

NO1

29 January 2003

FEB 14 2003

R ARMSTRONG PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

5714-01-F5T

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷: C07D 307/91, 333/76, 307/93, A61K 31/34, 31/38, C07D 405/04, 209/88, C07C 311/21	A1	(11) International Publication Number: WO 00/06561
		(43) International Publication Date: 10 February 2000 (10.02.00)
(21) International Application Number: PCT/US99/12273 (22) International Filing Date: 2 June 1999 (02.06.99) (30) Priority Data: 60/095,006 30 July 1998 (30.07.98) US (71) Applicant (for all designated States except US): WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road, Morris Plain, NJ 07950 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): O'BRIEN, Patrick, Michael [US/US]; 5501 Green Road, Stockbridge, MI 49285 (US). PICARD, Joseph, Armand [US/US]; 44809 Saltz Road, Canton, MI 48187 (US). SLISKOVIC, Drago, Robert [GB/US]; 3679 Hedgerow Drive, Saline, MI 48176 (US). (74) Agents: RYAN, M., Andrea; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 (US) et al.		(81) Designated States: AE, AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report.  *G00002*
(54) Title: TRICYCLIC SULFONAMIDES AND THEIR DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES		
(57) Abstract Tricyclic sulfonamide compounds and derivatives are described as well as methods for the preparation and pharmaceutical compositions of same, which are useful as inhibitors of matrix metalloproteinases, particularly gelatinase A, collagenase-3, and stromelysin-1 and for the treatment of multiple sclerosis, atherosclerotic plaque rupture, aortic aneurysm, heart failure, left ventricular dilation, restenosis, periodontal disease, corneal ulceration, treatment of burns, decubital ulcers, wound healing, cancer, inflammation, pain, arthritis, osteoporosis, renal disease, or other autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes or other activated migrating cells, acute and chronic neurodegenerative disorders including stroke, head trauma, spinal cord injury, Alzheimer's disease, amyotrophic lateral sclerosis, cerebral amyloid angiopathy, AIDS, Parkinson's disease, Huntington's disease, prion diseases, myasthenia gravis, and Duchenne's muscular dystrophy.  *162162*		